NCT05544929
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05544929
Title A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers
Recruitment Active, not recruiting
Gender both
Phase Phase I
Variant Requirements Yes
Sponsors Novartis Pharmaceuticals
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | ITA | FRA | ESP | DEU | CAN

Facility Status City State Zip Country Details
Massachusetts General Hospital . Boston Massachusetts 02114 United States Details
Massachusetts General Hospital Boston Massachusetts 02114 United States Details
NYU School of Medicine New York New York 10015 United States Details
University of Pittsburgh Medical Center Pittsburgh Pennsylvania 15232 United States Details
SCRI Oncology Partners Nashville Tennessee 37203 United States Details
Novartis Investigative Site Toronto Ontario M5G 2M9 Canada Details
Novartis Investigative Site Guangzhou Guangdong 510080 China Details
Novartis Investigative Site Beijing 100036 China Details
Novartis Investigative Site Lyon 69373 France Details
Novartis Investigative Site Dresden Saxony 01307 Germany Details
Novartis Investigative Site Essen 45147 Germany Details
Novartis Investigative Site Hong Kong 999077 Hong Kong Details
Novartis Investigative Site Milan MI 20133 Italy Details
Novartis Investigative Site Modena MO 41124 Italy Details
Novartis Investigative Site Chuo Ku Tokyo 104 0045 Japan Details
Novartis Investigative Site Singapore 119074 Singapore Details
Novartis Investigative Site Seoul 03080 South Korea Details
Novartis Investigative Site Barcelona Catalonia 08035 Spain Details
Novartis Investigative Site Taipei 10002 Taiwan Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field